Psilocybin is a naturally occurring psychedelic compound that acts on serotonin 2A receptors in the brain. It can temporarily alter perception, mood, and cognition, often leading to changes in awareness, emotional processing, and sense of connection.

Psilocybin-assisted therapy combines the controlled use of psilocybin with professional psychological support. Sessions are conducted under the supervision of trained therapists or healthcare professionals and typically include preparation, dosing, and integration phases to ensure safety and therapeutic benefit.

Clinical studies suggest that psilocybin-assisted therapy may be effective for:

• Treatment-resistant depression
• End-of-life anxiety and existential distress
• Post-traumatic stress disorder (PTSD)
• Addiction (to opioids, alcohol, nicotine, and other substances)
• Obsessive-compulsive disorder (OCD)

Research is ongoing, and results are promising but not yet conclusive.

Psilocybin remains a controlled substance under the Controlled Drugs and Substances Act. However, Health Canada may grant exemptions under Section 56 or authorize use through the Special Access Program (SAP) for individuals with serious or life-threatening conditions when other treatments have failed. A small number of clinical trials and compassionate-use exemptions have been approved in Canada.

In clinical or therapeutic settings, psilocybin is usually administered orally in a capsule or tea. The experience lasts 4–6 hours, during which participants are monitored by trained professionals. Sessions are often preceded by counseling to prepare the individual and followed by integration therapy to help process the experience.

Common short-term effects include emotional intensity, nausea, or anxiety during the session. Serious adverse effects are rare when psilocybin is used in a supervised, clinical setting. However, it is not recommended for individuals with a personal or family history of psychosis or certain psychiatric conditions without professional assessment.

Psilocybin increases activity at serotonin 2A receptors, leading to changes in communication between brain networks. This “reset” effect may help disrupt rigid thought patterns associated with depression, anxiety, or addiction.

Many clinical trials report that improvements in mood, anxiety, and outlook can last weeks to months, and in some cases up to a year or longer. Long-term outcomes depend on follow-up therapy and individual psychological support.

Access is limited. Options include:

• Health Canada’s Special Access Program (SAP)
• Clinical trials at research institutions
• Section 56 exemptions for compassionate use in certain cases

TheraPsil and other non-profit organizations help eligible patients apply for legal access.